OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and sample collection devices in the United States, Europe, and internationally. The company is headquartered in Bethlehem, Pennsylvania.
| Revenue (TTM) | $113.02M |
| Gross Profit (TTM) | $47.77M |
| EBITDA | $-61.54M |
| Operating Margin | -78.40% |
| Return on Equity | -21.20% |
| Return on Assets | -10.60% |
| Revenue/Share (TTM) | $1.57 |
| Book Value | $4.51 |
| Price-to-Book | 0.87 |
| Price-to-Sales (TTM) | 2.45 |
| EV/Revenue | 0.959 |
| EV/EBITDA | 2.22 |
| Quarterly Earnings Growth (YoY) | 29.60% |
| Quarterly Revenue Growth (YoY) | -6.70% |
| Shares Outstanding | $68.85M |
| Float | $60.74M |
| % Insiders | 6.38% |
| % Institutions | 89.04% |
Volatility is currently expanding
BETHLEHEM, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. It will hold its quarterly conference call to discuss the results beginning at 5 p.m. Eastern Time on that day.
The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients. The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients.
BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions today announced U.S. Food and Drug Administration (FDA) clearance of its Colli-Pee™•Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche's tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) and run on Roche's cobas® 5800, 6800, and 8800 molecular diagnostic systems.
OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026.
BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026.
Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OSUR and any ticker you trade — then tracks every position and per-strategy win rate.
